Andrew Freistein is a Partner in Wenderoth’s pharmaceutical and chemical practice group. His practice includes preparing and prosecuting patent applications in the chemical and pharmaceutical arts, providing infringement and invalidity opinions, conducting due diligence, and analyzing patent term adjustments and patent term extensions.
Specifically, Andrew's practice focuses on:
- Small molecule drugs
- Pharmaceutical compositions
- Ophthalmic compositions
- Synthetic preparation
- Methods of treatment
- Drug delivery
- Dosage forms
- Glass Compositions
Andrew also conducts post-grant proceedings and was lead counsel in Takeda Pharmaceutical Company v. Array BioPharma Inc., IPR2015-00754, representing patent owner, Takeda, in its first ever inter partes review (IPR).
Andrew is an active member of the patent bar. He was a delegate of the AIPLA IP Practice in Japan Committee’s 2017 trip to Tokyo and Osaka, Japan, has been an Adjunct Professor at George Mason University Antonin Scalia Law School, has organized and moderated many webinars on chemical and pharmaceutical patent law, and has been the President of the Patent Lawyers Club of Washington.
Prior to entering private practice, Andrew was a Patent Examiner with the United States Patent and Trademark Office where he examined patent applications directed to heterocyclic organic chemistry.
When not practicing law, Andrew enjoys rooting for his hometown St. Louis Cardinals and the Mizzou Tigers, and spending time with his wife and two children.
- American Intellectual Property Law Association
- Patent Lawyers Club of Washington
- Intellectual Property Owner's Association
Speaker, “To Appeal, or Not to Appeal: That is the Question. Effective prosecution strategies after final rejection”, AIPLA Annual Meeting IP Practice in Japan Committee Pre-Meeting Seminar, Washington, DC, October 17, 2017.
U.S. Delegate and Speaker, “U.S. Patent Prosecution Tips: Markush Groups, Provisional Applications and Ex Parte Appeals, Oh My!”, 2017 AIPLA IP Practice in Japan Committee Delegation, April 23-28, Tokyo and Osaka, Japan.
- Speaker, “U.S. Patent Prosecution Tips: In Re: LF Centennial and Howmedica Osteonics Corp. v. Zimmer, Inc.”, AIPLA Annual Meeting IP Practice in Japan Committee Pre-Meeting Seminar, Washington, DC, October 26, 2016
- Speaker, “Double Patenting Rejections in U.S. Patent Prosecution”, Japan External Trade Organization (JETRO), 17th IPG Meeting, Washington, DC, July 27, 2016
- Speaker, “Learning the ABC’s of Patent Term Adjustment”, AIPLA IP Practice in Japan Premeeting at the 2015 Annual Meeting, Washington, DC, October 22, 2015
- Moderator and Organizer, "Best Practices to Secure Allowance of Patent Application Claims using Evidence", AIPLA webinar, March 3, 2015
- Moderator and Organizer, "Recent Developments and Strategies for Avoiding or Overcoming Obviousness-Type Double Patenting Issues", AIPLA webinar, May 8, 2014
- Moderator and Organizer, " A Practitioner's Guide: Recent Development in Patent Term Adjustment - Exelixis I and Exelixis II", AIPLA webinar, May 29, 2013
- Wenderoth Attorney is Part of U.S. Delegation to Japan
April 9, 2018
- Wenderoth Hosts JETRO IPG Meeting
February 27, 2018
- USPTO Revises MPEP
February 1, 2018
- CAFC Poised to Reverse PTAB in IPR Decision
December 12, 2017
- USPTO EXTENDS AFCP 2.0 & QPIDS PILOT PROGRAMS ANOTHER YEAR
September 11, 2017
- USPTO Initiates Post-Prosecution Pilot Program (P3)
August 2, 2016
- USPTO to Accelerate Examination of Cancer Treatment Applications
June 30, 2016
- USPTO Produces Inter Partes Review Motion to Amend Study
May 9, 2016
- Federal Circuit: PTAB Not Required to Address Every Claim Challenged in IPR
February 18, 2016
- Congratulations to Andrew B. Freistein On Becoming a Wenderoth Partner
January 4, 2016
- USPTO Revises the M.P.E.P.
November 3, 2015
- AFCP 2.0 Extended Through September 30, 2016
September 28, 2015
- USPTO Announces Proposed Rule Changes for AIA Trials
August 21, 2015
- USPTO Announces Expedited Patent Appeal Pilot Program
June 16, 2015